Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM4HYMS)

Drug Name

ABT-888 Drug Info

Synonyms

Veliparib; 912444-00-9; ABT-888; ABT 888; ABT-888 (Veliparib); Veliparib (ABT-888); ABT888; UNII-01O4K0631N; 2-[(2R)-2-Methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide; CHEBI:62880; 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide; (R)-2-(2-methylpyrrolidin-2-yl)-1H-benzo[d]imidazole-4-carboxamide; 01O4K0631N; 2-[(2R)-2-Methylpyrrolidin-2-yl]-1H-benimidazole-4-; (2r)-2-(7-Carbamoyl-1h-Benzimidazol-2-Yl)-2-Methylpyrrolidinium; Veliparib dihydrochloride

Indication

Disease Entry	ICD 11	Status	REF
Breast cancer	2C60-2C65	Phase 3	[1]
Epithelial ovarian cancer	2B5D	Phase 3	[2]
Non-small-cell lung cancer	2C25.Y	Phase 3	[3]
Ovarian cancer	2C73	Phase 3	[3]
Melanoma	2C30	Phase 2	[2]

Cross-matching ID

PubChem CID: 45480520
CAS Number: CAS 912445-05-7
TTD Drug ID: DM4HYMS

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Poly [ADP-ribose] polymerase (PARP)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Olaparib	DM8QB1D	Ovarian cancer	2C73	Approved	[5]
Rucaparib	DM9PVX8	Ovarian cancer	2C73	Approved	[6]
Talazoparib	DM1KS78	Breast cancer	2C60-2C65	Approved	[7]
MK-4827	DMLYGH4	Ovarian cancer	2C73	Phase 3	[4]
BSI-201	DMM0VO3	Solid tumour/cancer	2A00-2F9Z	Phase 3	[8]
Rubraca rucaparib	DM25TMP	Ovarian cancer	2C73	Phase 3	[3]
INO-1001	DM5L8QT	Brain cancer	2A00	Phase 3	[9]
BGP-15	DMYDM68	Type-2 diabetes	5A11	Phase 2	[10]
BGB-290	DMRO6XT	Ovarian cancer	2C73	Phase 2	[3]
2X-121	DMX9MSL	Breast cancer	2C60-2C65	Phase 2	[3]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Poly [ADP-ribose] polymerase (PARP)	TTEBCY8	NOUNIPROTAC	Modulator	[4]

------------------------------------------------------------------------------------

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7417).
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
5	2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
6	2016 FDA drug approvals. Nat Rev Drug Discov. 2017 Feb 2;16(2):73-76.
7	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
8	Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro. Clin Cancer Res. 2012 Mar 15;18(6):1655-62.
9	Therapeutic injection of PARP inhibitor INO-1001 preserves cardiac function in porcine myocardial ischemia and reperfusion without reducing infarct size. Shock. 2010 May;33(5):507-12.
10	BGP-15, a PARP-inhibitor, prevents imatinib-induced cardiotoxicity by activating Akt and suppressing JNK and p38 MAP kinases. Mol Cell Biochem. 2012 Jun;365(1-2):129-37.